ReviewDiseases (Basel, Switzerland)2025
Overdiagnosis and Overtreatment in Prostate Cancer.
Review in Diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.Annals of medicine · 2026Review
- Socioeconomic differences in prostate cancer diagnosis and stage following the introduction of Rapid Access Prostate Clinics in Ireland.ESMO real world data and digital oncology · 2026Article
- [Current status of prostate cancer screening research].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Review
- AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020-present).Expert opinion on therapeutic patents · 2026Review
- Toward a Structured Imaging Reporting System for Kidney Masses: The Molecular Imaging Perspective on KI-RADS.Molecular imaging and biology · 2026Review
- Integrative Bioinformatics and Machine Learning Analysis Identifies Novel Molecular Biomarkers in Prostate Adenocarcinoma.International journal of molecular sciences · 2026Article
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Exploring shared decision-making in prostate cancer screening within primary health care settings in Portugal: a cross-sectional study.BMC primary care · 2026Article
- Inflammatory and Epigenetic Biomarkers in Prostate Disease: Current Evidence, Clinical Limitations, and Future Multimarker Strategies.Diagnostics (Basel, Switzerland) · 2026Review
- Biparametric MRI in prostate cancer: utility of whole-prostate and whole-lesion histogram and texture analysis for clinically significant prostate cancer.Japanese journal of radiology · 2026Article
- Urinary Epithelial Cell Adhesion Molecule (EpCAM) as a Noninvasive Biomarker for Detecting Clinically Significant Prostate Cancer in Men With Equivocal PSA Levels.BioMed research international · 2026Article
- Glandular Density and Glandular Volume of the Peripheral Zone as Novel Pre-Biopsy Biometric Parameters: A Retrospective Pilot Study.Research and reports in urology · 2026Article
- Using Artificial Intelligence as a Risk Prediction Model in Patients with Equivocal Multiparametric Prostate MRI Findings.Cancers · 2025Review
- Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics.EJNMMI research · 2025Review
- Global, regional, and national burden and trends of prostate cancer in elderly from 1990 to 2021: results from global burden of disease 2021.World journal of surgical oncology · 2025Article
- Artificial intelligence in prostate cancer: navigating the new frontier of precision uro-oncology.American journal of clinical and experimental urology · 2025Review
- CD133 Immunoexpression in Prostatic Acinar Adenocarcinomas.Current health sciences journalArticle
- AI in Prostate Cancer Screening & Diagnosis: A Registry-Based Study of ClinicalTrials.gov Trials.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is one of the most common malignancies among men worldwide. While prostate-specific antigen (PSA) screening has improved early detection, it has also led to significant challenges regarding overdiagnosis and overtreatment. Overdiagnosis involves identifying indolent tumors unlikely to affect a patient's lifespan, while overtreatment refers to unnecessary interventions that can cause adverse effects such as urinary incontinence, erectile dysfunction, and a reduced quality of life. This review highlights contributing factors, including the limitations of PSA testing, advanced imaging techniques like multi-parametric MRI (mpMRI), medical culture, and patient expectations. The analysis emphasizes the need for refining screening protocols, integrating novel biomarkers (e.g., PCA3, TMPRSS2-ERG), and adopting conservative management strategies such as active surveillance to minimize harm. Risk-based screening and shared decision-making are critical to balancing the benefits of early detection with the risks of unnecessary treatment. Additionally, systemic healthcare factors like financial incentives and malpractice concerns exacerbate overuse. This review advocates for updated clinical guidelines and personalized approaches to optimizing patient outcomes while reducing the strain on healthcare resources. Addressing overdiagnosis and overtreatment through targeted interventions will improve the quality of life for PCa patients and enhance the efficiency of healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.